Ubamatamab redirects T cells via CD3 engagement to MUC16-expressing tumor cells, leveraging uniformly high MUC16 expression in LGSOC and enabling responses without molecular preselection. At 800 mg ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...
Following hematopoietic SCT (HSCT) for non-malignant disorders (NMDs) variable donor chimerism among lympho-hematopoietic lines may be observed. We retrospectively evaluated early post-HSCT, ...
Targeting the T-cell co-receptor cluster of differentiation 3 (CD3) in type 1 diabetes (T1D) mellitus may impede the autoimmune attack initiated by a triggering event, thus slowing or preventing ...
A condition called CD3 delta SCID is caused by a mutation in the CD3D gene, which prevents the production of the CD3 delta protein that is needed for the normal development of T cells from blood stem ...
Intracellular retention of TCRαβ/CD3 and CD7 to generate novel allogeneic CAR-T cells targeting CD7 for treating T-cell malignancies. Non-clinical evaluation of NT-112, an autologous T cell product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results